Minireviews
Copyright ©The Author(s) 2023.
World J Clin Cases. Mar 26, 2023; 11(9): 1903-1917
Published online Mar 26, 2023. doi: 10.12998/wjcc.v11.i9.1903
Table 3 The comparison of methods in studies on frontal electroencephalogram alpha asymmetry of response to antidepressant treatment
Ref.Sample
Age (yr)
Intervention time% femaleDiagnosis of depressionEEG detail
Experimental group
Control group
Experimental group
Control group
Reference montage
EO/EC
Recording length (min)
Alpha range (Hz)
Arns et al[70], 2016EG: 236 Escitalopram, 251 Sertraline, 235 Venlafaxine-XRCG: 336 controlsM = 38.85 (Escitalopram), M = 38.34 (Sertraline), M = 38.46 (Venlafaxine-XR), M = 37.84 (MDD) M = 36.99 (Controls)8 wk57.03DSM–IV; MINI; HRSDAM E0+EC28–13
Vinne et al[71], 2019EG: 136 treatment with escitalo pram, 169 treatment with sertraline, 188 treatment with venlafaxine-extended release8 wk54.47MINI; HRSD; VQIDS-SRAM E0+EC48–13
Bares et al[72], 2019EG: 57 SSRIs, 46 SNRIs M = 46.04 (SSRIs), M = 44.83 (SNRIs)1 wk74.76DSM IV; MADRS; CGICzEC108–13
Szumska et al[73], 2021EG: 12 Mindfulness groupCG: 8 control groupM = 32.40 (Mindfulness group) M = 35.00 (Control group)8 wk55CES-D; MINICzE0+EC38–13
Keune et al[74], 2011EG: 78 MDD; 40 MBCT groupCG: 37 a wait-list condition M = 48.93 (MBCT group)M = 45.24 (wait-list group)8 wk74.03DSM-IVAME0+EC88--13
Barnhofer et al[75], 2007EG: 10 MBCT CG: 12 treatment-as-usualM = 48.00 (MBCT)M = 38.60 (treatment-as-usual)8 wk50MINIAEE0+EC88–13
Gollan et al[77], 2014EG: 37 MDD; Behavioral activationCG: 35 non-MDD16 wk62.50 DSM-IV; IDS-CAME0+EC88–13
Allen et al[14], 2004EG: 30 nonpharmacological intervention8 wk100DSM–IV; HRSDCz; AM, ARE0+EC88–13
Spronk et al[78], 2008EG: 8 MDD; rTMS TreatmentM = 42.60 (rTMS Treatment)37.50 BDI; SCIAM E0+EC2alpha 1 (8–11); alpha 2 (11–13)
Wang et al[80], 2016EG: 7 neurofeedback group M = 47.436 wk78.57DSM-IVCzEC58–12
Vlcek et al[79], 2020EG: 9 LF rTMS responder CG: 16 LF rTMS non-responders4 wk80MINI; MADRS; CGICzEC108–12; 8–10; 10–12